Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Incyte reports robust revenue growth and strategic focus on pediatric market

Incyte's Q4 2022 earnings call showcased strong revenue growth, driven by successful product launches and advancements in the clinical development pipeline.
While facing challenges in market adoption and operational dynamics, Incyte's strategic focus on pediatric patients and engagement with healthcare professionals positions it well for future growth.
Opportunities lie in expanding market reach for Opzelura, exploring new therapeutic applications, and enhancing market penetration efforts through strategic partnerships and product differentiation.
Overall, Incyte's performance reflects a balance of solid financial results, strategic investments in innovation, and a focus on addressing market challenges to drive sustainable growth.

Incyte (INCY) reports robust Q1 growth, eyes international expansion

Incyte's strong Q1 performance driven by Jakafi and Opzelura demand sets the stage for future growth and diversification.
Focusing on high-potential programs and commitment to biologics position Incyte for value creation and market expansion.
Challenges in inventory management and pricing strategies are being addressed as the company eyes multiple launches and international expansion.

Incyte excels in Q2 with strong revenue growth and strategic advancements

Incyte's Q2 2023 performance showcased strong revenue growth driven by key products and successful clinical studies, positioning the company for future success.
The company's focus on innovative therapies and strategic leadership appointments underpin its commitment to advancing in oncology and dermatology.
While facing challenges in revenue guidance and clinical trial progress, Incyte's openness to M&A and growth opportunities signals a proactive approach to driving future expansion.

Incyte reports strong Q3 earnings, focuses on pipeline expansion

Incyte's Q3 earnings reflect robust revenue growth and positive clinical development progress. The company is navigating challenges of patent expiration while focusing on expanding market access and advancing pipeline programs.

Incyte reports robust 2023 earnings, eyes global growth opportunities

Incyte's strong financial performance in 2023 was driven by revenue growth across key products and successful launches like Opzelura.
The company's focus on innovative clinical programs and R&D advancements positions it well for future growth and market expansion.
Challenges in reimbursement, patient retention, and regulatory compliance require strategic planning, while opportunities in global partnerships and market expansion offer avenues for continued success.

Incyte reports strong Q1 growth, eyes oncology opportunities ahead

Incyte delivered solid financial performance in Q1 2024, driven by revenue growth and strong product sales.
The company faces challenges from operational disruptions and competitive landscapes but is well-positioned for growth.
Strategic strengths in pipeline development, financial stability, and market focus position Incyte for future success.
Opportunities in new product launches, market expansion, and capital deployment offer avenues for continued growth.

Incyte reports robust Q2 earnings, raises guidance on key products

Incyte's Q2 2024 performance reflects strong revenue growth, strategic acquisitions, and a focus on high-potential pipeline assets. While facing challenges with rising expenses and pipeline restructuring, the company is well-positioned to capitalize on opportunities in innovative drug development and positive patient outcomes.

Incyte reports robust Q3 earnings, eyes high-impact launches by 2030

Overall, Incyte's Q3 2024 earnings call showcased strong revenue growth, promising product developments, and a focus on expanding its product portfolio and pipeline for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Novartis

The Food and Drug Administration will expedite its review of capmatinib.

Potential Lung Cancer Drug from Incyte and Novartis to Get a Priority Review from FDA

The FDA accepts Incyte's (INCY) NDA for capmatinib and grants Priority Review.

Incyte's (INCY) Capmatinib NDA Gets Priority Review From FDA

Alliance Resource Partners

Repligen

These three stocks have major events coming up this month -- and it's not just the release of earnings that investors will be watching.

Stocks to Watch in February

A failed study disappointed investors, but the company's pipeline should withstand the blow.

Here's Why Incyte Stock Tumbled 16.3% in January

Incyte (INCY) posts positive top-line results from late-stage TRuE-AD2 study on ruxolitinib cream to treat adolescent and adult patients with atopic dermatitis. The study achieves its main goal.

Incyte's Phase III Atopic Dermatitis Study Meets Primary Goal

Incyte (INCY) closed at $76.46 in the latest trading session, marking a +0.51% move from the prior day.

Incyte (INCY) Gains But Lags Market: What You Should Know

But the biotech won't release details about how well it works until later.

Incyte's Eczema Drug Ruxolitinib Works in a Late-Stage Clinical Trial

Incyte stock popped in premarket trading Tuesday after the biotech company said its cream eczema treatment, dubbed ruxolitinib cream, succeeded in the first of two pivotal studies.
The post Could An Eczema Treatment Pull Incyte Stock Out Of Its Downtrend?

Could An Eczema Treatment Pull Incyte Stock Out Of Its Downtrend?

Eli Lilly

The results could help expand use of the drug that's currently approved to treat rheumatoid arthritis.

Eli Lilly and Incyte's Olumiant Helps Eczema Patients in a Late-Stage Clinical Trial

Nektar Therapeutics

Regeneron Pharmaceuticals

Pricing concerns have resurfaced among biotech stocks this month. The recent pullback could offer a buying opportunity.

3 Biotech Stocks Nearing Support

Incyte's reliance on one product might be an issue.

Incyte Stock Is Down: Buy the Dip?

Axsome Therapeutics

Two pharma stocks, one riding a wave of enthusiasm and one getting unfairly punished, look appealing from a long-term standpoint.

2 Top Growth Stocks to Buy in January

Incyte (INCY) closed at $76.53 in the latest trading session, marking a -0.79% move from the prior day.

Incyte (INCY) Stock Sinks As Market Gains: What You Should Know

The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.

Incyte's Application for Pemigatinib Gets EMA's Validation

Geron

Formed in the early ‘90s, Geron and Incyte exemplify the long and often tumultuous road it takes to translate science into medicines.

Better Buy: Geron vs. Incyte

Incyte has seen a continued increase in sales, yet real diversification efforts have not paid off just yet.

Incyte: Looking More Appealing, Yet Pipeline Conversion Is Required

Incyte (INCY) news for Friday about a recent clinical trial failing to meet its endpoints has INCY stock taking a beating.
The post Incyte News: INCY Stock Tumbles 10% on Experimental Drug Study Failure appeared first on InvestorPlace.

Incyte News: INCY Stock Tumbles 10% on Experimental Drug Study Failure

An important clinical trial failed, reminding investors of the company's poor track record with its pipeline.

Here's Why Incyte Fell as Much as 12.6% Today

Incyte stock tumbled to a three-month low Friday amid a flurry of price-target cuts following the biotech company's late-stage failure in never-before-treated acute graft vs. host disease.

Incyte Stock Pummeled As Late-Stage Failure Casts Doubt On Pipeline

Incyte (INCY) fails to meet goals in the phase III study on itacitinib for the treatment of first-line acute GVHD.

Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study

Incyte stock crashed late Thursday after the biotech company's treatment for never-before-treated patients with graft vs. host disease, a transplant complication, failed in a study.

Leading Biotech Stock Crashes After Promising Drug Fails Late-Stage Test

Incyte Corp. INCY, -1.55% shares fell more than 12% in after-hours trading Thursday after the company revealed that a phase-3 study of a drug failed to reach its goal.

Incyte stock slammed after study fails to hit goal

Seagen

Few biotech companies ever reach that valuation, and if they do, you should snap them up for your portfolio.

A $20 Billion Sweet Spot in Biotech

In the latest trading session, Incyte (INCY) closed at $88.39, marking a -0.44% move from the previous day.

Incyte (INCY) Stock Moves -0.44%: What You Should Know

Incyte (INCY) outperforms the industry year to date on strong Jakafi sales.

News for Incyte Stock (INCY)